Endocrine Abstracts

The treatment of osteoporosis consists of either antiresorptive or anabolic approaches. While there are a number of antiresorptive options available (i.e. bisphosphonates, SERMs and denosumab), teriparatide (PTH 1-34) is currently the only bone anabolic agent approved in the EU. The PTH-related protein (PTHrP) analogue abaloparatide and the sclerostin antibody romosozumab are two anabolic agents that are in the approval process for the treatment of postmenopausal osteoporosis....